Pioglitazone is an agonist of PPARγ hence the binding of pioglitazone to its ligand leads to the upregulation of antioxidant responses, a phenomenon which has been reported to be deficient in FRDA patients. The gene discussed is PPARG; the disease is Friedreich ataxia.